Ten-Year All-Cause Mortality in Presumably Healthy Subjects on Lipid-Lowering Drugs (from the Prospective Epidemiological Study of Myocardial Infarction [PRIME] prospective cohort)

American Journal of Cardiology

Volumn 103, Issue 3, 2009, Pages 381-386

  Gardette, Virginie ^a   Bongard, Vanina ^a   Dallongeville, Jean ^b   Arveiler, Dominique ^c   Bingham, Annie ^d   Ruidavets, Jean Bernard ^a   Amouyel, Philippe ^b   Haas, Bernadette ^c   Ducimetière, Pierre ^d   Ferrières, Jean ^a,e  

^a INSERM   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d HÔPITAL PAUL BROUSSE   (France)

^e CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CIPROFIBRATE; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PRAVASTATIN; SIMVASTATIN;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC DISEASE; CONTROLLED STUDY; DYSLIPIDEMIA; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL;

ANTILIPEMIC AGENTS; CAUSE OF DEATH; CLOFIBRIC ACID; DYSLIPIDEMIAS; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED;

EID: 58749117007     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.09.092     Document Type: Article

References (23)

1. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J., Shepherd J., and Wenger N.K. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
2. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., Ford I., Gaw A., Hyland M., Jukema J.W., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
3. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., and Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol And Recurrent Events Trial investigators. N Engl J Med 335 (1996) 1001-1009
4. MRC/BHF Heart Protection Study Collaborative Group. Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
5. Dale K.M., Coleman C.I., Henyan N.N., Kluger J., and White C.M. Statins and cancer risk: a meta-analysis. JAMA 295 (2006) 74-80
6. Rossebo A.B., Pedersen T.R., Boman K., Brudi P., Chambers J.B., Egstrup K., Gerdts E., Gohlke-Barwolf C., Holme I., Kesaniemi Y.A., et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 359 (2008) 1343-1356
7. Ducimetiere P., Ruidavets J.B., Montaye M., Haas B., and Yarnell J. Five-year incidence of angina pectoris and other forms of coronary heart disease in healthy men aged 50-59 in France and Northern Ireland: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study. Int J Epidemiol 30 (2001) 1057-1062
8. Empana J.P., Ducimetiere P., Arveiler D., Ferrieres J., Evans A., Ruidavets J.B., Haas B., Yarnell J., Bingham A., Amouyel P., and Dallongeville J. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations?. The PRIME Study. Eur Heart J 24 (2003) 1903-1911
9. Yarnell J.W. The PRIME study: classical risk factors do not explain the severalfold differences in risk of coronary heart disease between France and Northern Ireland. Prospective Epidemiological Study of Myocardial Infarction. QJM 91 (1998) 667-676
10. Tunstall-Pedoe H., Kuulasmaa K., Amouyel P., Arveiler D., Rajakangas A.M., and Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 90 (1994) 583-612
11. Marques-Vidal P., Ruidavets J.B., Cambou J.P., and Ferrieres J. Trends in the prevalence, awareness and treatment of hypercholesterolemia in South-western France, 1985-1997. CVD Prev 3 (2000) 18-25
12. National Cholesterol Education Program Expert Panel Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 106 (2002) 3143-3421
13. Ford I., Murray H., Packard C.J., Shepherd J., Macfarlane P.W., and Cobbe S.M. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 357 (2007) 1477-1486
14. WHO. Cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators. Lancet 2 (1980) 379-385
15. The Bezafibrate Infarction Prevention Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) Study. Circulation 102 (2000) 21-27
16. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glasziou P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
17. Tenkanen L., Manttari M., Kovanen P.T., Virkkunen H., and Manninen V. Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med 166 (2006) 743-748
18. Saha S.A., Kizhakepunnur L.G., Bahekar A., and Arora R.R. The role of fibrates in the prevention of cardiovascular disease. A pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 154 (2007) 943-953
19. Newman T.B., and Hulley S.B. Carcinogenicity of lipid-lowering drugs. JAMA 275 (1996) 55-60
20. Sleijfer S., van der Gaast A., Planting A.S., Stoter G., and Verweij J. The potential of statins as part of anti-cancer treatment. Eur J Cancer 41 (2005) 516-522
21. Farwell W.R., Scranton R.E., Lawler E.V., Lew R.A., Brophy M.T., Fiore L.D., and Gaziano J.M. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 100 (2008) 134-139
22. Browning D.R., and Martin R.M. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 120 (2007) 833-843
23. Strandberg T.E., Pyorala K., Cook T.J., Wilhelmsen L., Faergeman O., Thorgeirsson G., Pedersen T.R., and Kjekshus J. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364 (2004) 771-777